Revance Therapeutics Inc (FRA:RTI)
€ 3.5 -0.08 (-2.23%) Market Cap: 358.58 Mil Enterprise Value: 642.04 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices Call Transcript

May 19, 2020 / 12:30PM GMT
Release Date Price: €18.1 (-4.74%)
Operator

Welcome to the Revance Therapeutics call discussing the company's acquisition of HintMD. (Operator Instructions) As a reminder, this conference is being recorded today, Tuesday, May 19, 2020. I would now turn the call over to Jeanie Herbert, Senior Director of Investor Relations. Please go ahead.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Jonathan. With me on today's call from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; and Chief Commercial Officer, Aesthetics & Therapeutics, Dustin Sjuts. This morning, Revance Therapeutics announced the acquisition of HintMD, a privately held company that has developed a proprietary financial technology platform for aesthetic practices. If you have not received the news release and would like to read it or if you'd simply like to be added to the company's distribution list, you can access both at investors.revance.com. Today's conference call includes a slide presentation, which we will reference as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot